Edwards Lifesciences Corp

EWNYSE · USD
107.15USD0.00 (+1.28%)
699

Edwards Lifesciences Corp (EW) Covered Calls

Edwards Lifesciences Corp trades in the Medical Devices industry with an IV Rank of 16.27%, low versus the past year. EW's highest covered call setup is the $110.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 2.66% out of the money with 7 days to expiration, a 2.85% return until expiration, and a 148.42% theoretical annualized return. Across the setups shown, annualized returns run from 81.69% to 148.42% at strikes between $110.00 and $145.00, with 7 to 126 days to expiration, as of Nov 13, 2026.

Read more

Running EW covered calls helps you generate income from Edwards Lifesciences Corp shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best EW covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If EW stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling EW covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given EW covered call is worth writing.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation.

2026-11-207110.002.660.200.60305.002.85148.42-0.19+0.213,2670.40
2026-12-1835120.0011.990.150.751300.0012.13126.52-0.14+0.112380.60
2027-01-1563130.0021.330.050.602290.0021.37123.82-0.05+0.06270.55
2027-02-1998140.0030.660.150.653300.0030.80114.71-0.14+0.0680.50
2027-03-19126145.0035.320.100.703795.0035.42102.60-0.09+0.0500.60
2027-02-1998135.0025.990.400.852825.0026.3698.20-0.37+0.09480.45
2027-01-1563125.0016.660.250.951810.0016.8997.87-0.23+0.111850.70
2027-03-19126140.0030.660.250.853310.0030.8989.49-0.23+0.071580.60
2026-12-1835115.007.330.752.00860.008.0383.70-0.70+0.253851.25
2027-02-1998130.0021.330.651.202350.0021.9381.69-0.61+0.12160.55

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryMedical Devices
  • SectorHealthcare
  • IV Rank16.27% Low
  • Market cap (M$)61,611
  • 52 weeks high0.33%
  • 52 weeks low43.52%
  • Analyst recommendationBuy
    1.52
  • Target price$115.48
    7.77% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-09
  • P/E62.40
  • Future P/E31.46
  • EPS (ttm)1.72
  • EPS growth next 5 years14.45%

As of Nov 13, 2026